A phase 2, randomized, double-blind, placebo-controlled, parallel-group study of CP-195543 and celecoxib dual therapy in the treatment of the signs and symptoms of rheumatoid arthritis in subjects who are inadequately controlled on methotrexate

Trial Profile

A phase 2, randomized, double-blind, placebo-controlled, parallel-group study of CP-195543 and celecoxib dual therapy in the treatment of the signs and symptoms of rheumatoid arthritis in subjects who are inadequately controlled on methotrexate

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2014

At a glance

  • Drugs CP 195543 (Primary) ; Celecoxib
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Mar 2008 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 13 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top